Artiva Biotherapeutics, Inc.
ARTV
Jodie situation report
Artiva Biotherapeutics, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 23 of 24 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 20 directly disclosed connections are confirming.
- At least 16 of 24 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as XNCR begins moving with the group.
Invalidation: The live read weakens if participation falls to 8 of 24 members or fewer.
Who this business touches
The relationships behind ARTV
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ACETFiling-linked namecompetitorMay 8, 2026 ▾
“Our known biopharmaceutical competitors that are developing allogeneic NK, CAR-NK, or CAR-T cell therapies or T-cell engaging bispecific antibodies include, but may not be limited to, the following: Adicet Bio, Inc., Allogene Therapeutics, Inc., Amgen Inc., A…”
ALLOAllogene Therapeutics, Inc.competitorMay 8, 2026 ▾
“Our known biopharmaceutical competitors that are developing allogeneic NK, CAR-NK, or CAR-T cell therapies or T-cell engaging bispecific antibodies include, but may not be limited to, the following: Adicet Bio, Inc., Allogene Therapeutics, Inc., Amgen Inc., A…”
Depended on by
NKTRNektar TherapeuticscompetitorNov 7, 2025 ▾
“For NKTR-255, we believe companies that are currently researching and developing engineered IL-15 biologics and cell therapies that could compete with this drug candidate include Artiva Biotherapeutics, Fate Therapeutics, ImmunityBio, Inc., Nkarta Therapeutic…”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 17 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ARTV is currently a Participant in the organic co-movement group Rare Disease Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.